10766350

~~10771661 .5~~ Page 1

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	May 12	EXTEND option available in structure searching
NEWS 4	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS 5	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAplus
NEWS 6	May 27	CAplus super roles and document types searchable in REGISTRY
NEWS 7	Jun 28	Additional enzyme-catalyzed reactions added to CASREACT
NEWS 8	Jun 28	ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS 9	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS 10	Jul 30	BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS 11	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS 12	AUG 02	CAplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS 13	AUG 02	STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS 14	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS 15	AUG 04	Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004

NEWS EXPRESS	JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:36:29 ON 24 AUG 2004

Patel <8/24/2004>

10766355


```
=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 14:36:39 ON 24 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   23 AUG 2004  HIGHEST RN 731771-88-3
DICTIONARY FILE UPDATES:  23 AUG 2004  HIGHEST RN 731771-88-3

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10771861.5

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```

10766360



G1 CH2,CH,NH2

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss full
FULL SEARCH INITIATED 14:37:04 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 797779 TO ITERATE

 50.1% PROCESSED  400000 ITERATIONS                                1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.05

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:       797779 TO   797779
PROJECTED ANSWERS:               1 TO        5

L2             1 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     155.42     155.63

FILE 'CAPLUS' ENTERED AT 14:37:15 ON 24 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 24 Aug 2004 VOL 141 ISS 9
FILE LAST UPDATED: 23 Aug 2004 (20040823/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L3 1 L2

=> d l3 fbib hitstr abs total

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:661381 CAPLUS
DN 135:226873
TI Preparation and formulation of azetidines for pharmaceutical use
IN Achard, Daniel; Bouchard, Herve; Bouquerel, Jean; Filoche, Bruno; Grisoni, Serge; Hittinger, Augustin; Myers, Michael
PA Aventis Pharma S.A., Fr.
SO PCT Int. Appl., 249 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001064632	A1	20010907	WO 2001-FR600	20010301
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			FR 2000-2775	A 20000303
FR 2805818	A1	20010907	FR 2000-2775	20000303
FR 2805818	B1	20020426		
EP 1263720	A1	20021211	EP 2001-909937	20010301
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			FR 2000-2775	A 20000303
			WO 2001-FR600	W 20010301
BR 2001008871	A	20030429	BR 2001-8871	20010301
			FR 2000-2775	A 20000303
			WO 2001-FR600	W 20010301
JP 2003525268	T2	20030826	JP 2001-563475	20010301
			FR 2000-2775	A 20000303
			WO 2001-FR600	W 20010301
EE 200200487	A	20040216	EE 2002-487	20010301

			FR 2000-2775	A	20000303
			WO 2001-FR600	W	20010301
US 2001027193	A1	20011004	US 2001-798072		20010302
US 6479479	B2	20021112			
			FR 2000-2775	A	20000303
			US 2000-200399P	P	20000427
NO 2002004175	A	20021029	NO 2002-4175		20020902
			FR 2000-2775	A	20000303
			WO 2001-FR600	W	20010301
BG 107056	A	20030731	BG 2002-107056		20020903
			FR 2000-2775	A	20000303
			WO 2001-FR600	W	20010301
US 2003055033	A1	20030320	US 2002-242575		20020912
			FR 2000-2775	A	20000303
			US 2000-200399P	P	20000427
			US 2001-798072	A1	20010302

OS MARPAT 135:226873

IT **359402-80-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and formulation of azetidines for pharmaceutical use)

RN 359402-80-5 CAPLUS

CN Azetidine, 3-[(3,5-difluorophenyl)(methylsulfonyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

GI



I



II

AB Azetidines, such as I and II [R2, R3 = aryl, heteroaryl; R4 = alkyl, arylalkyl, cycloalkyl, heteroaryl, heteroarylalkyl, etc.; R5 = H, acyl, alkylsulfonyl, carboxyl, carboxamido, etc.; R6 = H, CN, alkylamino, alkylthio, etc.], were prepared for use as pharmaceuticals with potential usefulness in treating conditions such as neurol. disorders, cancer, immunol. disorders, and substance abuse. Thus, I (R2 = R3 = C6H4-4-Cl, R4

= SO2Me, R5 = C6H3-3,5-F2, R6 = H) was prepared via a multistep synthetic sequence starting from MeSNa, BrCH2C6H3-3,5-F2, BrCH(C6H4-4-Cl)2, and 1-(diphenylmethyl)-3-azetidinone. Data for specific biol. activities were not given, however, pharmaceutical formulations for delivery were presented.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s GPCR and l2
L4 0 GPCR AND L2

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	7.02	162.65

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.70	-0.70

STN INTERNATIONAL LOGOFF AT 14:37:53 ON 24 AUG 2004

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	May 12	EXTEND option available in structure searching
NEWS 4	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS 5	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAplus
NEWS 6	May 27	CAplus super roles and document types searchable in REGISTRY
NEWS 7	Jun 28	Additional enzyme-catalyzed reactions added to CASREACT
NEWS 8	Jun 28	ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS 9	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS 10	Jul 30	BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS 11	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS 12	AUG 02	CAplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS 13	AUG 02	STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS 14	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS 15	AUG 04	Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004

NEWS EXPRESS	JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:45:39 ON 24 AUG 2004

```
=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 14:45:48 ON 24 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   23 AUG 2004  HIGHEST RN 731771-88-3
DICTIONARY FILE UPDATES:  23 AUG 2004  HIGHEST RN 731771-88-3

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10766300.1

L1      STRUCTURE UPLOADED

=> s l1 end
COMBINATION OF STRUCTURE AND TEXT TERMS NOT VALID
The query entered contains both search terms created by
structure-building or screen commands and text search terms.  L#s
created via the STRUCTURE or SCREEN commands must be searched in the
structures files separately from text terms or profiles.  The L#
answer sets from structure searches can be used in crossover searches
and can be combined with text terms.

=> d l1
L1 HAS NO ANSWERS
L1              STR
```



G1 CH2,CH,NH2

G2 C,O,S,N,CH2,CH,SO2,NH

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss full
FULL SEARCH INITIATED 14:46:33 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 545649 TO ITERATE

 73.3% PROCESSED  400000 ITERATIONS                                 4 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.05

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       545649 TO   545649
PROJECTED ANSWERS:               4 TO       12

L2             4 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   155.84     156.05

FILE 'CAPLUS' ENTERED AT 14:46:43 ON 24 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is

FILE COVERS 1907 - 24 Aug 2004 VOL 141 ISS 9
FILE LAST UPDATED: 23 Aug 2004 (20040823/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L3 5 L2

=> d l3 fbib hitstr abs total

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:392358 CAPLUS
DN 137:119060
TI Structural Requirements for Inhibition of the Neuronal Nitric Oxide Synthase (NOS-I): 3D-QSAR Analysis of 4-Oxo- and 4-Amino-Pteridine-Based Inhibitors
AU Matter, Hans; Kotsonis, Peter; Klingler, Otmar; Strobel, Hartmut; Froehlich, Lothar G.; Frey, Armin; Pfleiderer, Wolfgang; Schmidt, Harald H. H. W.
CS Molecular Modeling, Aventis Pharma, Frankfurt am Main, 65926, Germany
SO Journal of Medicinal Chemistry (2002), 45(14), 2923-2941
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 137:119060
IT **443889-32-5**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation and QSAR of 4-oxo- and 4-amino-pteridine-based neuronal NOS inhibitors)
RN 443889-32-5 CAPLUS
CN 4(1H)-Pteridinone, 2-amino-5,6,7,8-tetrahydro-6-[(methylsulfonyl)methyl]- (9CI) (CA INDEX NAME)



AB The family of homodimeric nitric oxide synthases (NOS I-III) catalyzes the generation of the cellular messenger nitric oxide (NO) by oxidation of the substrate L-arginine. The rational design of specific NOS inhibitors is

of therapeutic interest in regulating pathol. NO levels associated with sepsis, inflammatory, and neurodegenerative diseases. The cofactor (6R)-5,6,7,8-tetrahydrobiopterin (H4Bip) maximally activates all NOSs and stabilizes enzyme quaternary structure by promoting and stabilizing dimerization. Here, we describe the synthesis and three-dimensional (3D) quant. structure-activity relationship (QSAR) anal. of 65 novel 4-amino- and 4-oxo-pteridines (antipterins) as inhibitors targeting the H4Bip binding site of the neuronal NOS isoform (NOS-I). The exptl. binding modes for two inhibitors complexed with the related endothelial NO synthase (NOS-III) reveal requirements of biol. affinity and form the basis for ligand alignment. Different alignment rules were derived by building other compds. accordingly using manual superposition or a genetic algorithm for flexible superposition. Those alignments led to 3D-QSAR models (comparative mol. field anal. (CoMFA) and comparative mol. similarity index anal. (CoMSIA)), which were validated using leave-one-out cross-validation, multiple analyses with two and five randomly chosen cross-validation groups, perturbation of biol. activities by randomization or progressive scrambling, and external prediction. An iterative realignment procedure based on rigid field fit was used to improve the consistency of the resulting partial least squares models. This led to consistent and highly predictive 3D-QSAR models with good correlation coeffs. for both CoMFA and CoMSIA, which correspond to exptl. determined NOS-II and -III H4Bip binding site topologies as well as to the NOS-I homol. model binding site in terms of steric, electrostatic, and hydrophobic complementarity. These models provide clear guidelines and accurate activity predictions for novel NOS-I inhibitors.

RE.CNT 111 THERE ARE 111 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:608717 CAPLUS
DN 133:207678
TI Preparation of sulfonamide derivs. as amyloid β production inhibitors useful in treating or preventing diseases related to Aβ
IN Smith, David W.; Munoz, Benito; Srinivasan, Kumar; Bergstrom, Carl P.; Chaturvedula, Prasad V.; Deshpande, Milind S.; Keavy, Daniel J.; Lau, Wai Yu; Parker, Michael F.; Sloan, Charles P.; Wallace, Owen B.; Wang, Henry Hui
PA Merck & Co., Inc., USA; Bristol-Myers Squibb Company
SO PCT Int. Appl., 377 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000050391	A1	20000831	WO 2000-US4560	20000222
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 1999-121906P	P 19990226
				US 1999-122746P	P 19990226
				US 1999-122748P	P 19990226

			US 1999-130994P	P 19990423
			US 1999-130995P	A2 19990423
EP 1159263	A1	20011205	EP 2000-910293	20000222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
			US 1999-121906P	P 19990226
			US 1999-122746P	P 19990226
			US 1999-122748P	P 19990226
			US 1999-130994P	P 19990423
			US 1999-130995P	P 19990423
			WO 2000-US4560	W 20000222
BR 2000008965	A	20020226	BR 2000-8965	20000222
			US 1999-121906P	P 19990226
			US 1999-122746P	P 19990226
			US 1999-122748P	P 19990226
			US 1999-130994P	P 19990423
			US 1999-130995P	P 19990423
			WO 2000-US4560	W 20000222
JP 2002537376	T2	20021105	JP 2000-600975	20000222
			US 1999-121906P	P 19990226
			US 1999-122746P	P 19990226
			US 1999-122748P	P 19990226
			US 1999-130994P	P 19990423
			US 1999-130995P	P 19990423
			WO 2000-US4560	W 20000222
NZ 514453	A	20030429	NZ 2000-514453	20000222
			US 1999-121906P	P 19990226
			US 1999-122746P	P 19990226
			US 1999-122748P	P 19990226
			US 1999-130994P	P 19990423
			US 1999-130995P	P 19990423
			WO 2000-US4560	W 20000222
AU 773273	B2	20040520	AU 2000-32410	20000222
			US 1999-121906P	P 19990226
			US 1999-122746P	P 19990226
			US 1999-122748P	P 19990226
			US 1999-130994P	P 19990423
			US 1999-130995P	P 19990423
			WO 2000-US4560	W 20000222
ZA 2001006646	A	20021113	ZA 2001-6646	20010813
			US 1999-121906P	P 19990226
NO 2001004135	A	20010927	NO 2001-4135	20010824
			US 1999-121906P	P 19990226
			US 1999-122746P	P 19990226
			US 1999-122748P	P 19990226
			US 1999-130994P	P 19990423
			US 1999-130995P	P 19990423
			WO 2000-US4560	W 20000222

OS MARPAT 133:207678

IT **290328-54-0P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of sulfonamide derivs. as amyloid β production inhibitors useful in treating or preventing diseases related to Aβ)

RN 290328-54-0 CAPLUS

CN Piperidine, 3-[(methylsulfonyl)methyl]- (9CI) (CA INDEX NAME)



GI



I

AB Title compds. [(D)(G)CHN(E)SO2(J); D = H, alkyl, heterocycle, halo, alkoxyl, ester, amide; G = alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, (CHR1)nO(CHR2)mCONR3R4, heterocycle, aryl, amine, amide, ester, ether, carbamate; D-G = cyclic; n = 1, 2, 3, 4; m = 0, 1, 2, 3, 4; R1, R2, R3, R4 are independently H, alkyl; R3-R4 = cyclic; E = H, alkyl, alkenyl, alkynyl, heterocycle, aryl, alkoxyl, amide, sulfonyl, sulfonamidyl, sulfide; J = alkyl, alkenyl, alkynyl, aryl, heterocycle, polycyclic; J-E = cyclic], pharmaceutically acceptable salts, and composition comprising title compds. are prepared Title compds. can act to modulate production of amyloid β protein (APP751, APP695wt, APP670/671, APP670/671/717, sAPP, α-sAPP, β-sAPP) and are useful in the prevention or treatment of a variety of diseases; such diseases are amyloid angiopathy, cerebral amyloid angiopathy, systemic amyloidosis, Alzheimer's disease, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, inclusion body myositis, and Down's syndrome. Thus, the title compound I was prepared and tested.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:731828 CAPLUS
DN 126:7997
TI Preparation of heterocyclic tricyclic compounds useful for inhibition of g-protein function and for treatment of cell proliferative diseases
IN Afonso, Adriano; Baldwin, John J.; Doll, Ronald J.; Li, Ge; Mallams, Alan K.; Njoroge, F. George; Rane, Dinanath F.; Reader, John C.; Rossman, Randall R.
PA Schering Corporation, USA; Pharmacopeia, Inc.
SO PCT Int. Appl., 135 pp.
CODEN: PIXXD2
DT Patent

LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 9631478	A1	19961010	WO 1996-US4172		19960403
	W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU					
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
				US 1995-418323	A	19950407
	IL 117798	A1	20011125	IL 1996-117798		19960402
				US 1995-418323	A	19950407
	CA 2217499	AA	19961010	CA 1996-2217499		19960403
				US 1995-418323	A	19950407
	AU 9655279	A1	19961023	AU 1996-55279		19960403
	AU 719990	B2	20000518			
				US 1995-418323	A	19950407
				WO 1996-US4172	W	19960403
	EP 819121	A1	19980121	EP 1996-912469		19960403
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, LT, LV, FI					
				US 1995-418323	A	19950407
				WO 1996-US4172	W	19960403
	BR 9604787	A	19980707	BR 1996-4787		19960403
				US 1995-418323	A	19950407
				WO 1996-US4172	W	19960403
	CN 1187189	A	19980708	CN 1996-194571		19960403
				US 1995-418323	A	19950407
	JP 10511981	T2	19981117	JP 1996-530364		19960403
	JP 3038017	B2	20000508			
				US 1995-418323	A	19950407
				WO 1996-US4172	W	19960403
	NZ 306665	A	20000128	NZ 1996-306665		19960403
				US 1995-418323	A	19950407
				WO 1996-US4172	W	19960403
	TW 462968	B	20011111	TW 1996-85103970		19960405
				US 1995-418323	A	19950407
	US 5801175	A	19980901	US 1996-713324		19960913
				US 1995-418323	B2	19950407
				WO 1996-US4172	A	19960403
	NO 9704610	A	19971208	NO 1997-4610		19971006
				US 1995-418323	A	19950407
				WO 1996-US4172	W	19960403
	US 6214827	B1	20010410	US 1998-108124		19980623
				US 1995-418323	B2	19950407
				WO 1996-US4172	W	19960403
				US 1996-713324	A1	19960913

PATENT FAMILY INFORMATION:
FAN 1998:585371

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 5801175	A	19980901	US 1996-713324		19960913
				US 1995-418323	B2	19950407
				WO 1996-US4172	A	19960403
	WO 9631478	A1	19961010	WO 1996-US4172		19960403
	W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IS, JP,					

KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

			US 1995-418323	A	19950407
US 6214827	B1	20010410	US 1998-108124		19980623
			US 1995-418323	B2	19950407
			WO 1996-US4172	W	19960403
			US 1996-713324	A1	19960913

OS MARPAT 126:7997
IT **183591-37-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heterocyclic tricyclic compds. useful for inhibition of g-protein function and for treatment of cell proliferative diseases)
RN 183591-37-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 2-[2-[(cyclopropylmethyl)sulfonyl]ethyl]-, 1,1-dimethylethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; A, B = H, halogen, alkyl; R1 = COCN(NH2)CH2SH, CH2CH(NH2)CH2SH, COCH(NH2)CH2NH2, CH2CH(SH)CH2NH2, etc.; W = CH, CH2, O, S; X = C, CH, N; the dotted lines represent optional double bonds and when present W = CH and X = C], useful for inhibiting the Ras function and therefore inhibiting the abnormal growth of cells (e.g., cancer) via the inhibition of farnesyl protein transferase, are prepared and I-containing formulations presented. Thus, pyridine derivative II was prepared and demonstrated a tumor cell IC50 of 12.5 μM.

L3 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:710529 CAPLUS
DN 126:8134
TI Preparation of antineoplastic carbonylpiperazinyl and -piperidinyl derivatives which inhibit farnesyl protein transferase
IN Doll, Ronald J.; Mallams, Alan K.; Afonso, Adriano; Rane, Dinanath F.; Njoroge, F. George; Rossman, Randall A.; Baldwin, John J.; Li, Ge; Reader, John C.
PA Schering Corporation, USA; Pharmacopeia, Inc.
SO PCT Int. Appl., 84 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 9631501	A1	19961010	WO 1996-US4169		19960403
	W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU					
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
				US 1995-418319	A	19950407
	ZA 9602694	A	19961003	ZA 1996-2694		19960403
				US 1995-418319	A	19950407
	CA 2217351	AA	19961010	CA 1996-2217351		19960403
	CA 2217351	C	20030318			
				US 1995-418319	A	19950407
	AU 9654326	A1	19961023	AU 1996-54326		19960403
				US 1995-418319	A	19950407
				WO 1996-US4169	W	19960403
	EP 820452	A1	19980128	EP 1996-911440		19960403
	EP 820452	B1	20030604			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI					
				US 1995-418319	A	19950407
				WO 1996-US4169	W	19960403
	JP 10511979	T2	19981117	JP 1996-530361		19960403
	JP 3038016	B2	20000508			
				US 1995-418319	A	19950407
				WO 1996-US4169	W	19960403
	AT 242231	E	20030615	AT 1996-911440		19960403
				US 1995-418319	A	19950407
				WO 1996-US4169	W	19960403
	ES 2194986	T3	20031201	ES 1996-911440		19960403
				US 1995-418319	A	19950407

OS MARPAT 126:8134
IT **183591-37-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of antineoplastic carbonylpiperazinyl and -piperidinyl derivs. which inhibit farnesyl protein transferase)
RN 183591-37-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 2-[2-[(cyclopropylmethyl)sulfonyl]ethyl]-, 1,1-dimethylethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



I



II



III

AB The title compds. [I, II; R1 = carbonyl- or sulfonyl-containing moiety; R2, R3 = aminocarbonyl- or carboxyalkyl-containing moiety; Z = (un)substituted quinolinyl, (un)substituted quinolinylalkyl, (un)substituted naphthyl, (un)substituted naphthylalkyl, (un)substituted diphenylmethyl, (un)substituted diphenylalkyl, etc.] (e.q., III; IC50 for farnesyl protein transferase <10 mM), useful for inhibiting the Ras function and therefore inhibiting the abnormal growth of cells (e.g., cancer), are prepared and I-containing formulations presented.

L3 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:56265 CAPLUS
DN 124:76535
TI Tetrahydropteridine derivatives as inhibitors of nitric oxide synthase
IN Pfleiderer, Wolfgang; Schmidt, Harald; Henning, Rainer
PA Cassella AG, Germany
SO Ger. Offen., 19 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	DE 4418097	A1	19951130	DE 1994-4418097		19940524
	CA 2188267	AA	19951130	CA 1995-2188267		19950511
				DE 1994-4418097	A	19940524
	WO 9532203	A2	19951130	WO 1995-EP1785		19950511
	WO 9532203	A3	19951228			
	W: CA, JP, US					

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

			DE 1994-4418097	A	19940524
EP 760818	A1	19970312	EP 1995-921745		19950511
EP 760818	B1	20020306			

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE

			DE 1994-4418097	A	19940524
			WO 1995-EP1785	W	19950511
JP 10500417	T2	19980113	JP 1995-530022		19950511
			DE 1994-4418097	A	19940524
			WO 1995-EP1785	W	19950511
AT 214068	E	20020315	AT 1995-921745		19950511
			DE 1994-4418097	A	19940524
			WO 1995-EP1785	W	19950511
PT 760818	T	20020830	PT 1995-921745		19950511
			DE 1994-4418097	A	19940524
ES 2173185	T3	20021016	ES 1995-921745		19950511
			DE 1994-4418097	A	19940524

OS MARPAT 124:76535

IT **172758-35-9**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetrahydropteridine derivs. as inhibitors of nitric oxide synthase)

RN 172758-35-9 CAPLUS

CN 4(1H)-Pteridinone, 2-amino-5,6,7,8-tetrahydro-6-[(methylsulfonyl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

GI



I

AB Tetrahydropteridine derivs. I [X = O, NH; R1 = H, Me, C1-5 alkanoyl, nicotinoyl, (1-methyl-3-pyridinio)carbonyl; R2, R5-R7 = H, Me; R3 = H, Me, Et, PhCH2, C1-5 alkanoyl, Bz, nicotinoyl, PhCH2O2C, etc.; R4 = H, C1-4 alkylthio, SOmMe, NH2, NHMe, NMe2, OH, etc.; or R3R4 = C(O)O; m = 1, 2], as analogs of the NO synthase cofactor tetrahydrobiopterin, are inhibitors

of NO synthase and of endogenous NO production, and are useful in treatment of diseases characterized by elevated NO levels (e.g. hypotensive shock, type I diabetes, atherosclerosis). Thus, I-3HCl (X = O, R1-R3 = R5-R7 = H, R4 = NHMe) at 100 μM inhibited NO synthase from pig brain by 57.5% in the presence of 2 μM tetrahydrobiopterin. Pills were prepared containing active agent 50, corn starch 100, lactose 60, CaHPO4 30, soluble starch 5, Mg stearate 10, and colloidal silicic acid 5 mg.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	30.54	186.59

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.50	-3.50

STN INTERNATIONAL LOGOFF AT 14:47:04 ON 24 AUG 2004